Home » Newsletters » BioWorld Science

BioWorld Science

May 31, 2006

View Archived Issues

PD-0325901 inhibits hepatocellular carcinoma growth in vivo

GW-427353 inhibits cholinergic contraction in human colon

ZK-156979 has therapeutic effect in experimental colitis

Spectrum presents Q1 highlights

Ono updates latest developments in pipeline

Milestones in Metabolex's diabetes and obesity collaboration with Astellas

Phase IIa trial studies Phosphagenics' transdermal morphine

Orally available calpain inhibitor provides in vivo neuroprotection against retinal ischemia

BioInvent considers protocol amendment for phase I/II study of BI-201 for HIV

Canadian notice of deficiency for GlucaGen

Shire disappointed at NICE's recommendation on patients with mild Alzheimer's

PEP-005 Topical studied for cutaneous squamous cell carcinoma in situ

Herceptin plus Arimidex prolongs PFS in advanced HER2 breast cancer

Sphingosine 1-phosphate S1P1 receptor agonists emerge from Merck R&D

Bristol-Myers Squibb presents antitumor activity of new VEGFR-2 inhibitor

Pfizer present new oral PDE5 inhibitor as a candidate for male erectile dysfunction

Recent patents describe new anticoagulants

Novel alpha 1a/1d adrenoreceptor antagonists claimed for BPH treatment

Agents with potential for the treatment of metabolic disorders described in recent patents

New report from Prous Science reviews treatment options for patients with muscular dystrophy

Oracea approved for rosacea

ISTA begins pivotal studies for once-daily Xibrom

Phase II study of LE-SN-38 in metastatic colorectal cancer begins enrollment

Ortec to file HDE for cryopreserved OrCel in epidermolysis bullosa

European approval for Zostavax

Astellas returns Japanese strontium ranelate rights to Servier

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...